Frankly Speaking About Family Medicine

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490

Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice.

Episode resource links:

Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995

Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open. 

Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology.

Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke. 

Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke. 

Guest: Susan Feeney, DNP, FNP-BC, NP-C
 
Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 

The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-489

Overview: Join us as we discuss lipoprotein(a) testing—including when it adds value and when it may not. We review the evidence behind this increasingly requested cardiovascular risk marker, equipping you with the knowledge to counsel patients, understand current and emerging treatment options, and optimize evidence-based strategies to reduce overall cardiovascular disease risk.

Episode resource links:

Eur J Clin Invest. 2025 Oct 3:e70127. doi: 10.1111/eci.70127.

Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147
Progress in Cardiovascular Diseases, 84, 2024, Pages 27-33, https://doi.org/10.1016/j.pcad.2024.05.007

Guest: Jillian Joseph, MPAS, PA-C
 
Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 

The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-488

Overview: Stimulants have long been used to treat attention-deficit/hyperactivity disorder (ADHD); however, their mechanisms of action have been unclear. In this episode, we review a study on functional MRI to assess brain function in patients with ADHD, providing insight into the effects of stimulant medications.

Episode resource links:

https://doi.org/10.1016/j.cell.2025.11.039

Guest: Robert A. Baldor MD, FAAFP
 
Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 

The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-487

Overview: With online access driving a dramatic surge in gambling addiction, primary care clinicians are increasingly positioned on the front lines of identification and intervention. This episode brings you practical screening tools, evidence-based treatment strategies, and prevention approaches to confidently address gambling disorder in your patients.

Episode resource links:

Yeola A, Allen MR, Desai N, et al. Growing Health Concern Regarding Gambling Addiction in the Age of Sportsbooks. JAMA Intern Med. 2025;185(4):382–389. doi:10.1001/jamainternmed.2024.8193

Moreira D, Azeredo A, Dias P. Risk Factors for Gambling Disorder: A Systematic Review. J Gambl Stud. 2023;39(2):483-511. doi:10.1007/s10899-023-10195-1

Ioannidis K, Del Giovane C, Tzagarakis C, et al. Pharmacological management of gambling disorder: A systematic review and network meta-analysis. Compr Psychiatry. 2025;137:152566. doi:10.1016/j.comppsych.2024.152566

Ulisse, K., Albitar, J., Aromin, J. T., & Berry, J. (2025). Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation. Brain sciences, 15(9), 980. https://doi.org/10.3390/brainsci15090980

 

Identifying a gambling disorder:  Mass.gov Practice Guidelines for Treating Gambling-Related Problems.  Includes brief screening, Assessment, Diagnosis, Hotlines and Resources. 

Gambling Addiction Calendar:  Free app 

Reset App: Free

Guest: Jill M. Terrien PhD, ANP-BC 
 
Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 

The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-486

Overview: Optimizing diabetes management starts with choosing the right medication for the patient. Listen in as we discuss current prescribing recommendations, empowering you to confidently compare medication classes and select therapies that best fit individual patient needs—while prioritizing kidney protection to reduce the risk of long-term complications.

Episode resource links:

Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes. JAMA Intern Med. Published online January 20, 2026. doi:10.1001/jamainternmed.2025.7409

Samson SL, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305-340.

Guest: Jillian Joseph, MPAS, PA-C
 
Music Credit: Matthew Bugos

Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com 

The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.